Mankind Pharma Ltd. (IN:MANKIND)
:MANKIND
Want to see IN:MANKIND full AI Analyst Report?
MANKIND Stock Chart & Stats
₹2202.55
-₹40.15(-1.38%)
At close: 4:00 PM EST
₹2202.55
-₹40.15(-1.38%)
Day’s Range― - ―
52-Week Range₹1,909.90 - ₹2,726.75
Previous CloseN/A
Volume302.66K
Average Volume (3M)10.08K
Market Cap
₹979.15B
Enterprise Value₹1.04T
Total Cash (Recent Filing)₹31.05B
Total Debt (Recent Filing)₹83.69B
Price to Earnings (P/E)50.7
Beta0.54
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.04%
Share Statistics
EPS (TTM)42.77
Shares Outstanding412,909,200
10 Day Avg. Volume5,924
30 Day Avg. Volume10,081
Financial Highlights & Ratios
PEG Ratio-7.55
Price to Book (P/B)5.08
Price to Sales (P/S)5.80
P/FCF Ratio43.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,830.00Price Target Upside28.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)58.19
Revenue Forecast (FY)₹159.79B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelMankind's mix of prescription branded formulations plus an OTC consumer-health portfolio creates diversified, recurring revenue streams. Physician-driven prescriptions provide stable trade sales while consumer brands generate repeat retail demand, reducing single-channel risk and supporting cash resilience over months.
Consistent Revenue GrowthSustained multi-year revenue growth indicates expanding product adoption and distribution scale. Consistent top-line expansion supports operational leverage, funding for marketing and R&D, and the ability to invest behind brands, which underpins durable competitive positioning over the medium term.
Solid Free Cash Flow GenerationConsistent positive free cash flow that covers a meaningful portion of earnings enhances financial flexibility. It supports reinvestment, dividend payments and debt reduction without relying on external financing, strengthening the firm's ability to execute strategic initiatives over the next several quarters.
Bears Say
Margin CompressionMaterial margin deterioration points to rising costs or adverse product mix that erode profitability even as sales grow. Lower margins reduce free cash conversion and limit room for reinvestment, making earnings more sensitive to cost inflation and competitive pricing over the medium term.
Weak Operating Cash ConversionOperating cash flow materially lagging reported earnings indicates weaker earnings quality, likely from working capital build or receivables. This reduces durable liquidity, constrains internal funding for growth, and raises the risk that earnings gains won't translate reliably into available cash.
Higher Leverage Vs HistoricalAlthough leverage recently improved, absolute debt remains higher than historical norms and ROE has declined, signaling lower returns on incremental capital. Elevated debt reduces balance-sheet flexibility and raises susceptibility to higher interest costs, limiting strategic optionality over coming quarters.
Mankind Pharma Ltd. News
MANKIND FAQ
What was Mankind Pharma Ltd.’s price range in the past 12 months?
Mankind Pharma Ltd. lowest stock price was ₹1909.90 and its highest was ₹2726.75 in the past 12 months.
What is Mankind Pharma Ltd.’s market cap?
Mankind Pharma Ltd.’s market cap is ₹979.15B.
When is Mankind Pharma Ltd.’s upcoming earnings report date?
Mankind Pharma Ltd.’s upcoming earnings report date is Aug 05, 2026 which is in 61 days.
How were Mankind Pharma Ltd.’s earnings last quarter?
Mankind Pharma Ltd. released its earnings results on May 19, 2026. The company reported ₹14 earnings per share for the quarter, beating the consensus estimate of ₹10.15 by ₹3.85.
Is Mankind Pharma Ltd. overvalued?
According to Wall Street analysts Mankind Pharma Ltd.’s price is currently Undervalued.
Does Mankind Pharma Ltd. pay dividends?
Mankind Pharma Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.04%. See more information on Mankind Pharma Ltd. dividends here
What is Mankind Pharma Ltd.’s EPS estimate?
Mankind Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mankind Pharma Ltd. have?
Mankind Pharma Ltd. has 412,909,200 shares outstanding.
What happened to Mankind Pharma Ltd.’s price movement after its last earnings report?
Mankind Pharma Ltd. reported an EPS of ₹14 in its last earnings report, beating expectations of ₹10.15. Following the earnings report the stock price went down -0.09%.
Which hedge fund is a major shareholder of Mankind Pharma Ltd.?
Currently, no hedge funds are holding shares in IN:MANKIND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mankind Pharma Ltd.
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.
MANKIND Stock 12 Month Forecast
Average Price Target
₹2,830.00
▲(28.49% Upside)
Technical Analysis
Alkem Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―
Zydus Lifesciences Limited
―